Study of Chemotherapy Plus Camrelizumab After Surgery for Stage IIA-IIIA Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining postoperative chemotherapy with immunotherapy for patients with stage IIA to IIIA non-small cell lung cancer after surgery. This Phase II, single-arm study addresses clinical challenges in postoperative adjuvant immunotherapy and aims to improve treatment recommendations for this patient group. Participants receive four cycles of chemotherapy combined with camrelizumab, an immunotherapy drug administered at 200 mg on day 1 of each 21-day cycle. After these cycles, patients continue with maintenance therapy using camrelizumab every three weeks for up to one year, or until the disease worsens or unacceptable side effects occur. The chemotherapy regimen used is determined by the researcher. During the study, participants are monitored through laboratory tests, physical evaluations, and assessments of overall health. The main measure of success is two-year disease-free survival, with additional follow-up for survival rates and treatment-related side effects up to five years. Researchers track safety and treatment effects regularly, and participants are followed for approximately up to five years to assess long-term outcomes.

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients